Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Baseline demographic, clinical and laboratory characteristics of patients | Spironolactone group (n=7) | Control group (n=9) | p Value: Calcitriol | 2 (28.6) | 2 (22.2) | 0.608
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were excluded if they had taken spironolactone up to three months prior to recruitment, presented with hypotension, defined as systolic blood pressure < 100 mmHg and/or diastolic blood pressure < 60 mmHg, had presented in the past three months with mean serum potassium > 6 mEq/L, reported malignant neoplasms or serious liver disease, had undergone heart surgery or stent placement, presented with cardiac arrhythmia or were pregnant.
Source: Methods.
This study was a prospective, randomized, open label, controlled, single-center trial.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study
Study design awaiting verification · Jornal Brasileiro de Nefrologia · 2019
Original publication title
Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
There is evidence that aldosterone plays a role in the pathogenesis of vascular calcification. The aim of this study was to evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, on the progression of coronary calcification (CC) in peritoneal dialysis patients and to identify the factors involved in this progression.
Source: Introduction:Abstract: What methods does the paper describe?
Thirty-three patients with a coronary calcium score (CCS) ≥ 30, detected through multi-detector computed tomography (MDCT) and expressed in Agatston units, were randomly assigned to a group receiving 25mg spironolactone per day for 12 months (spironolactone group) and a control group not receiving this drug. The primary outcome was a percentage change in CCS from baseline to end of the study (relative progression), when a further MDCT was conducted. Patients who had progression of CC were compared with those who did not progress.
Source: Methods:Abstract: Results
Sixteen patients, seven in the spironolactone group and nine in the control group, concluded the study. The relative progression of the CCS was similar in both groups, 17.2% and 27.5% in the spironolactone and control groups respectively. Fifty-seven percent of the treated patients and 67% of those in the control group presented progression in the CC scores (p = 0.697). Progressor patients differed from non-progressors because they presented higher levels of calcium and low-density lipoprotein cholesterol and lower levels of albumin.
Source: Results:Abstract: Conclusion
In peritoneal dialysis patients, spironolactone did not attenuate the progression of CC. However, large-scale studies are needed to confirm this observation. Disorders of mineral metabolism and dyslipidemia are involved in the progression of CC.
Source: Conclusion:Authors’ abstract
ABSTRACT
Introduction:
There is evidence that aldosterone plays a role in the pathogenesis of vascular calcification. The aim of this study was to evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, on the progression of coronary calcification (CC) in peritoneal dialysis patients and to identify the factors involved in this progression.
Methods:
Thirty-three patients with a coronary calcium score (CCS) ≥ 30, detected through multi-detector computed tomography (MDCT) and expressed in Agatston units, were randomly assigned to a group receiving 25mg spironolactone per day for 12 months (spironolactone group) and a control group not receiving this drug. The primary outcome was a percentage change in CCS from baseline to end of the study (relative progression), when a further MDCT was conducted. Patients who had progression of CC were compared with those who did not progress.
Results:
Sixteen patients, seven in the spironolactone group and nine in the control group, concluded the study. The relative progression of the CCS was similar in both groups, 17.2% and 27.5% in the spironolactone and control groups respectively. Fifty-seven percent of the treated patients and 67% of those in the control group presented progression in the CC scores (p = 0.697). Progressor patients differed from non-progressors because they presented higher levels of calcium and low-density lipoprotein cholesterol and lower levels of albumin.
Conclusion:
In peritoneal dialysis patients, spironolactone did not attenuate the progression of CC. However, large-scale studies are needed to confirm this observation. Disorders of mineral metabolism and dyslipidemia are involved in the progression of CC.
Publication and source details
Original title: Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study
Ana Paula Santana Gueiros; José Edevanilson de Barros Gueiros; Karina Tavares Nóbrega; Eveline Barros Calado; Marina Cadena da Matta; Leuridan Cavalcante Torres; Alex Sandro Rolland Souza; Dulce Elena Casarini; Aluizio Barbosa de Carvalho
Jornal Brasileiro de Nefrologia · 2019
Correspondence to: Ana Paula Santana Gueiros. E-mail: ana.s@uol.com.brAUTHORS CONTRIBUTIONS
Ana Paula Santana Gueiros, José Edevanilson de Barros Gueiros, Karina Tavares Nóbrega, Eveline Barros Calado, Marina Cadena da Matta, Leuridan Cavalcante Torres, Alex Sandro Rolland Souza, Dulce Elena Casarini, Aluizio Barbosa de Carvalho contributed substantially to the conception or design of the study; collection, analysis, or interpretation of data; writing or critical review of the manuscript; and final approval of the version to be published.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:25:17.286296+00:00
DOI: 10.1590/2175-8239-jbn-2019-0009 · PMC6788848